Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹2,851 Cr
up ₹661 Cr vs Mar 2020
- Stocks held
- 17
- down 2 vs Mar 2020
- Top 10 weight
- 74.7%
- of the portfolio in its ten largest
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In April 2020 it disclosed 17 stocks worth ₹2,851 Cr, up ₹661 Cr from Mar 2020. Its largest positions were Aurobindo Pharma Limited (11.0%), Dr. Reddy's Laboratories Limited (10.4%), Sun Pharmaceutical Industries Limited (10.3%); the ten largest together made up 74.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 79.6% of its equity. Cash and debt stood at 3.5%. Compared with Mar 2020 the fund entered 0 new stocks and exited 2.
Against 226 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
53%
Holds more cash than 53% of peers
What these mean: concentration · cash
Holdings in April 2020
Download CSVEvery line the fund disclosed, with the change against Mar 2020. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Aurobindo Pharma Limited | 10.98% | up 2.49 pts | ₹313 Cr | up ₹127 Cr | Added |
| Dr. Reddy's Laboratories Limited | 10.36% | down 0.69 pts | ₹295 Cr | up ₹53.4 Cr | Added |
| Sun Pharmaceutical Industries Limited | 10.27% | up 0.13 pts | ₹293 Cr | up ₹70.7 Cr | Added |
| Divi's Laboratories Limited | 9.00% | down 0.99 pts | ₹257 Cr | up ₹37.8 Cr | Added |
| Cipla Limited | 7.86% | down 1.80 pts | ₹224 Cr | up ₹12.6 Cr | Added |
| Lupin Limited | 7.33% | up 2.21 pts | ₹209 Cr | up ₹96.8 Cr | Added |
| Syngene International Limited | 4.86% | up 0.47 pts | ₹139 Cr | up ₹42.4 Cr | Added |
| Sanofi India Limited | 4.77% | down 0.37 pts | ₹136 Cr | up ₹23.6 Cr | Added |
| Fortis Healthcare Limited | 4.72% | down 0.51 pts | ₹135 Cr | up ₹20 Cr | Added |
| Thyrocare Technologies Limited | 4.53% | down 1.03 pts | ₹129 Cr | up ₹7.5 Cr | Added |
| Abbott India Limited | 4.36% | down 1.64 pts | ₹124 Cr | down ₹7.2 Cr | Trimmed |
| Biocon Limited | 4.36% | up 0.02 pts | ₹124 Cr | up ₹29.3 Cr | Added |
| Zydus Lifesciences Limited | 3.97% | up 0.32 pts | ₹113 Cr | up ₹33.2 Cr | Added |
| Alkem Laboratories Limited | 3.57% | down 0.06 pts | ₹102 Cr | up ₹22.3 Cr | Added |
| Cash, TREPS & receivables | 3.53% | up 2.14 pts | ₹101 Cr | up ₹70.2 Cr | Added |
| Narayana Hrudayalaya Limited | 2.78% | down 0.33 pts | ₹79.3 Cr | up ₹11.3 Cr | Added |
| Indoco Remedies Limited | 2.50% | up 0.34 pts | ₹71.2 Cr | up ₹24 Cr | Added |
| Healthcare Global Enterprises Limited | 0.26% | down 0.10 pts | ₹7.3 Cr | down ₹42 L | Trimmed |
What changed, Mar 2020 to Apr 2020
New New positions (0)
None.
Exited Exited (2)
- Apollo Hospitals Enterprise Limitedwas 0.5% · ₹11.4 Cr
- AstraZeneca Pharma India Limitedwas 0.1% · ₹2.1 Cr
Added Biggest additions
- Aurobindo Pharma Limitedup ₹127 Cr (+2.49% pts)
- Lupin Limitedup ₹96.8 Cr (+2.21% pts)
- Sun Pharmaceutical Industries Limitedup ₹70.7 Cr (+0.13% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Mar 2020, the weight rose most in Pharmaceuticals & Biotechnology (+1.3 pts) and Pharmaceuticals (+0.4 pts), and fell most in Healthcare Services (−1.7 pts).
- Pharmaceuticals & Biotechnology78.4% → 79.6%+1.3 pts
- Pharmaceuticals2.2% → 2.6%+0.4 pts
- Healthcare Services19.4% → 17.8%−1.7 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Oct 2019 | Jan 2020 | Mar 2020 | Apr 2020 |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.2% | 77.7% | 78.4% | 79.6% |
| Healthcare Services | 21.1% | 20.5% | 19.4% | 17.8% |
| Pharmaceuticals | 0.7% | 1.9% | 2.2% | 2.6% |
Allocation in Apr 2020change vs Mar 2020
- Pharmaceuticals & Biotechnology (11)79.6%▲ 1.3 pts
- Healthcare Services (5)17.8%▼ 1.7 pts
- Pharmaceuticals (1)2.6%▲ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Apr 2020
3.5%
▲ 2.1 pts vs Mar 2020
- Cash alone
- 3.5%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- −<0.1% – 3.5%
- lowest to highest · record 3.5% in Apr 2020
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.